欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2012, Vol. 17 ›› Issue (1): 55-58.

• 经验交流 • 上一篇    下一篇

中药新药I期临床试验中纤维蛋白原关联性判断的体会

鲁喦, 李涛, 贾增芹, 高蕊, 唐旭东   

  1. 中国中医科学院西苑医院神经内科,北京 100091
  • 收稿日期:2011-06-17 修回日期:2011-09-27 出版日期:2012-01-26 发布日期:2012-02-16
  • 通讯作者: 唐旭东,男,主任医师,博士生导师,主要从事消化系统疾病的临床医疗和研究。Tel: 010-62835001 E-mail:txdly@sina.com
  • 作者简介:鲁嵒,男,硕士,主治医师,主要从事神经系统疾病的临床医疗。Tel: 13661311325 E-mail: luyan-1001@hotmail.com
  • 基金资助:
    科技部重大新药创制(200800931-022)

Experience about causality assessment of fibrinogen in phase I clinical trial of Chinese herbal medicine

LU Yan, LI Tao, JIA Zeng-qin, GAO Rui, TANG Xu-dong   

  1. Department of Neuropathy, Xiyuan Hospital,China Academy of TCM Sciences,Beijing 100091,China
  • Received:2011-06-17 Revised:2011-09-27 Online:2012-01-26 Published:2012-02-16

摘要: 目的: 探讨I期临床试验中纤维蛋白原指标评价存在的问题及其解决办法。方法: 通过一个新药I期临床试验案例对受试者的纤维蛋白原检测结果进行分析。结果: 单次给药试验的30例受试者中,26例出现纤维蛋白原降低,但无量效关系;在随后的连续给药试验中加入安慰剂对照组,其结果纤维蛋白原在高低剂量组中无量效关系,试验药物组和安慰剂对照组纤维蛋白原出现一致性变化,证实纤维蛋白原的变化与试验药物无关。结论: 纤维蛋白原检测受到多种因素的影响,应规范操作过程减少对其的影响;应制定适当的检测指标纳入标准;必要时可增加安慰剂对照,采用多种手段对实验室不良事件的关联性进行综合判断。

关键词: I期临床试验, 纤维蛋白原, 关联性判断

Abstract: AIM: To explore the fibrinogen evaluation problems and solution in phase I clinical trials.METHODS: Through a new phase I trial,there were 54 cases in phase I clinical trial volunteers' fibrinogen test, and analysised the results.RESULTS: Fibrinogen change did not exist consistency ,between 30 cases in single dose trial,there were 26 cases fibrinogen reduced ; In subsequent continuous drug trials to join the comfort drug group, the results of the two groups still did not exist consistency between groups, trial drug and placebo group fibrinogen appear consistency changes ,confirm the changes of fibrinogen is none of test drug.CONCLUSION: Fibrinogen test is affected by many kinds of factors, should be standardized operation process to reduce the influence; identify proper testing index range and inclusion criteria; can install placebo group if necessary, using a variety of means for causality assessment of the laboratory adverse events.

Key words: Phase I clinical trial, Fibrinogen, Relevance judgment

中图分类号: